Boston's resTORbio Sets Terms for $85M IPO Post author:Sam Post published:January 16, 2018 Post category:BioPharma resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace You Might Also Like <b>Epicore BioNetworks Inc.</b> Reports Quarter Three Results For Fiscal Year 2017 For The Quarter Ended 31 March 2017, In U.S. Dollars May 17, 2017 TraceLink, Inc. Announces End-To-End Administration For Product Track, Alleviating Time-Intensive DSCSA Compliance Tasks For U.S. Hospitals And Pharmacies June 25, 2017 <b>University Of Denver</b> Libraries Select <b>Yewno</b> Discover Research Application May 18, 2017
<b>Epicore BioNetworks Inc.</b> Reports Quarter Three Results For Fiscal Year 2017 For The Quarter Ended 31 March 2017, In U.S. Dollars May 17, 2017
TraceLink, Inc. Announces End-To-End Administration For Product Track, Alleviating Time-Intensive DSCSA Compliance Tasks For U.S. Hospitals And Pharmacies June 25, 2017
